JAK1-SELEKTIVE INHIBITOREN

European patent · EP3571192 · In force

Register entry

Publication number
EP3571192
Application number
EP18701296
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 16, 2018
Published
Nov 27, 2019
Granted
Nov 30, 2022
Protection ends at the latest
Jan 15, 2038
Next annual fee due
Jan 31, 2027
IPC classes
C07D 403/04 (2006.01)
C07D 403/14 (2006.01)
A61K 31/506 (2006.01)
A61P 17/14 (2006.01)
A61P 37/00 (2006.01)
Priority
US 201762447057 P 17.01.2017
PCT application
PCT/EP2018/051038 16.01.2018
PCT publication
WO2018/134213 26.07.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  3. Feb 1, 2024

    Change

    Published in Swissreg on 01.02.2024

  4. Oct 11, 2023

    Change

    Published in Swissreg on 11.10.2023

  5. Feb 1, 2023

    Change

    Published in Swissreg on 01.02.2023

  6. Nov 30, 2022

    Granted

    Published in Swissreg on 30.11.2022

Parties

Holder

AstraZeneca AB

Astrazeneca AB

151 85 Södertälje, SE

Inventor

NILSSON, Karl, Magnus

431 83 Mölndal, SE

KETTLE, Jason, Grant

Cambridge CB2 0AA, GB

SU, Qibin

Wilmington, DE 19803, US

LEPISTÖ, Matti, Juhani

431 83 Mölndal, SE

KAWATKAR, Sameer, Pralhad

Wilmington, DE 19803, US

JOHANSSON, Johan, R.

431 83 Mölndal, SE

ÅSTRAND, Annika, Birgitta, Margareta

431 83 Mölndal, SE

BERGGREN, Anna, Ingrid, Kristina

431 83 Mölndal, SE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.